Suven Life Sciences secures 4 product patents for their NCE’s in China, Mexico and South Africa

13 Jul 2015 Evaluate

Suven Life Sciences (Suven) has secured patents in China (CN103443093) and South Africa (2013/01143, 2013/06328) to their New Chemical Entities (NCE’s) for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2031,2030 and 2031 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

Suven also secured a patent for their NCE in Mexico (326651) and the granted claims of this patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD) and the patent is valid through 2030.

With these new patents, Suven has a total of sixteen granted patents from China, nineteen granted patents from Mexico and twenty two granted patents from South Africa. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Sciences Share Price

129.60 2.20 (1.73%)
28-Jan-2026 11:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1614.90
Dr. Reddys Lab 1222.80
Cipla 1316.40
Zydus Lifesciences 890.20
Lupin 2122.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×